EU Approval Decision Imminent For First CD20xCD3 Bispecific Antibody
Executive Summary
If Roche gets the nod from the European Medicines Agency for mosunetuzumab this week, it could become the first company to market a CD20xCD3 bispecific antibody for follicular lymphoma.